Evidence map›Paper›PMID 38013968›Full record

ArticleClinical immunology communications2022

Myocarditis following Coronavirus vaccination.

Khouloud Ferchichi, Imen Aouinti, Ahmed Zaiem, Ghozlane Lakhoua, Widd Kaabi, Ons Charfi, Sarrah Kastalli, Riadh Daghfous, Sihem El Aidli

Open access · goldAbstract read
In one paragraph

Article in Clinical immunology communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Considerations on COVID-19 vaccination.Clinical immunology communications · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Khouloud FerchichiNational Center Chalbi Belkahia of Pharmacovigilance, 9 Avenue Dr Zouheïr Essafi, Tunis 1006, Tunisia.
Imen AouintiNational Center Chalbi Belkahia of Pharmacovigilance, 9 Avenue Dr Zouheïr Essafi, Tunis 1006, Tunisia.
Ahmed ZaiemNational Center Chalbi Belkahia of Pharmacovigilance, 9 Avenue Dr Zouheïr Essafi, Tunis 1006, Tunisia.
Ghozlane LakhouaNational Center Chalbi Belkahia of Pharmacovigilance, 9 Avenue Dr Zouheïr Essafi, Tunis 1006, Tunisia.
Widd KaabiNational Center Chalbi Belkahia of Pharmacovigilance, 9 Avenue Dr Zouheïr Essafi, Tunis 1006, Tunisia.
Ons CharfiNational Center Chalbi Belkahia of Pharmacovigilance, 9 Avenue Dr Zouheïr Essafi, Tunis 1006, Tunisia.
Sarrah KastalliNational Center Chalbi Belkahia of Pharmacovigilance, 9 Avenue Dr Zouheïr Essafi, Tunis 1006, Tunisia.
Riadh DaghfousNational Center Chalbi Belkahia of Pharmacovigilance, 9 Avenue Dr Zouheïr Essafi, Tunis 1006, Tunisia.
Sihem El AidliNational Center Chalbi Belkahia of Pharmacovigilance, 9 Avenue Dr Zouheïr Essafi, Tunis 1006, Tunisia.
Faculté de médecine de Tunis

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Myocarditis is an adverse reaction discovered after the marketing of SARS-CoV-2 mRNA vaccines. Nevertheless, this effect is not mentioned as an adverse reaction in the summary of product characteristics of other types of vaccines against this disease. Objective: In this work, we aim to present the cases of myocarditis after vaccination against COVID-19 reported to the national Tunisian centre of pharmacovigilance. Method: We present the cases of myocarditis reported after the COVID-19 vaccination. All cases are diagnosed according to Brighton's case definition of myocarditis. The vaccines causality assessment was estimated by the French imputability updated method of Bégaud et al. Results: We included five patients. The sex ratio (M/F) was 4. The mean age was 30 years. All patients had no notable cardiovascular history and did not report any significant past medical history. The onset of symptoms was two days post-vaccination in three patients. The predominant reported symptoms are chest pain and dyspnea in the five cases. Cardiac magnetic resonance imaging (MRI) confirmed the myocarditis diagnosis in four patients (not performed for one patient).All cases were classified as definitive cases according to the Brighton case definition of myocarditis. No patient required hospitalization in a cardiac intensive care unit. All the patients recovered from acute myocarditis within a few days. Conclusion: Reported cases of myocarditis post-COVID-19 vaccination in our population are rare, not severe, and have a quick favorable outcome.

Indexed as

Adverse drug eventCoronavirus vaccinemRNA vaccineMyocarditis

Identifiers

PMID38013968
PMCPMC9670591
OpenAlexW4309204634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.